MARKET

BCYC

BCYC

Bicycle Therapeutics Limited
NASDAQ
9.08
-0.41
-4.32%
After Hours: 9.08 0 0.00% 16:09 03/21 EDT
OPEN
9.43
PREV CLOSE
9.49
HIGH
9.67
LOW
9.08
VOLUME
258.79K
TURNOVER
--
52 WEEK HIGH
28.67
52 WEEK LOW
9.00
MARKET CAP
628.36M
P/E (TTM)
-3.1268
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BCYC last week (0310-0314)?
Weekly Report · 5d ago
Tracking Baker Brothers Portfolio - Q4 2024 Update
Seeking Alpha · 03/13 03:56
Bicycle Therapeutics Price Target Maintained With a $30.00/Share by Needham
Dow Jones · 03/11 11:07
Needham Reiterates Buy on Bicycle Therapeutics, Maintains $30 Price Target
Benzinga · 03/11 10:58
Weekly Report: what happened at BCYC last week (0303-0307)?
Weekly Report · 03/10 09:27
Weekly Report: what happened at BCYC last week (0224-0228)?
Weekly Report · 03/03 09:27
Eckert & Ziegler Enters Strategic Partnership With Bicycle Therapeutics For Radioisotope Supply And Contract Development And Manufacturing Of Bicycle Radio Conjugates
Benzinga · 02/27 14:08
BRIEF-Eckert & Ziegler Enters Partnership With Bicycle Therapeutics
Reuters · 02/27 14:03
More
About BCYC
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.

Webull offers Bicycle Therapeutics PLC (ADR) stock information, including NASDAQ: BCYC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCYC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCYC stock methods without spending real money on the virtual paper trading platform.